The Prognostic Significance of miR-613 in Malignant Tumors and Association with Clinical Characteristics: A Systematic Review and Meta-Analysis
Objectives: Previous studies have shown that microRNA-613 (miR-613) functions as a tumor suppressor gene in various organ tissues. Our meta-analysis aimed to systematically evaluate the prognostic role of miR-613 and its association with clinical characteristics of malignant tumors.
Methods: We searched the PubMed/MEDLINE, Web of Science, Cochrane Library, and Google Scholar databases for relevant studies until July 25, 2023. Then, We pooled individual data and estimated the overall Hazard ratio (HR) and Odds ratio (OR) of miR-613 for prognosis and patient characteristic linking evaluations, respectively.
Results: After selection, 14 eligible studies with 1510 patients enrolled in final analyses. The lower level of miR-613 expression is associated with advanced stages (OR=3.08, 95% confidence interval [CI]: 2.27-4.18), larger tumor size (OR=2.05, 95%CI: 1.11-3.78), and lymph-node metastasis (OR=3.62, 95%CI: 2.55-5.14). Notably, downregulated miR-613 is associated with inferior progression-free survival (adjusted HR=1.65, 95%CI: 1.31-2.10) and overall survival (adjusted HR=1.83, 95%CI: 1.59-2.11). No significant heterogeneity was found in the analyses (I2=0%, P-values were 0.473 and 0.685, respectively).
Conclusion: The results of this study indicate that low miR-613 expression is associated with advanced stages, larger tumor size, and lymph node metastasis in malignant tumors. Besides, low miR-613 is a poor prognosis indicator for PFS and OS.
1. Allemani C, Matsuda T, Carlo VD, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000 14 (CONCORD-3): Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023– 75.
2. Fu Z, Wang L, Li S, Chen F, Au-Yeung KK, Shi C. MicroRNA as an important target for anticancer drug development. Front Pharmacol 2021;12:736323.
3. Mei J, Xu R, Hao L, Zhang Y. MicroRNA-613: A novel tumor suppressor in human cancers. Biomed Pharmacother 2020;123:109799.
4. Yan Z, Yin H, Lin G. CircDDX42 accelerates the development of pancreatic cancer via miR-613/ID4/PI3K/AKT axis. Onco Targets Ther 2020;13:10945–57.
5. Duan W, Pan S, Zhai Y, Deng Q, Ren W, Du C, et al. miR-613 suppresses renal cell carcinoma proliferation, invasion and migration by regulating the AXL/AKT pathway. Exp Biol Med 2023;248:281–92.
6. Hu G, Ma J, Zhang J, Chen Y, Liu H, Huang Y, et al. Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway. Mol Ther 2021;29:2979–94.
7. Deng L, Yin Q, Liu S, Luo D. MicroRNA-613 enhances nasopharyngeal carcinoma cell radiosensitivity via the DNA methyltransferase 3B/tissue inhibitor of matrix metalloproteinase-3/ signal transducer and activator of transcription-1/forkhead box O-1 axis. Dis Markers 2022;2022:5699275.
8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 2021;18:e1003583.
9. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Dec 13, 2023.
10. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
11. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: A hands-on guide. London: CRC Press; 2021. 12. Shim SR, Kim SJ, Lee J. Diagnostic test accuracy: Application and practice using R software. Epidemiol Health 2019;41:e2019007.
13. Guan S, Wang C, Chen X, Liu B, Tan B, Liu F, et al. MiR-613: A novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma. Tumour Biol 2016;37:4383–91.
14. Hu J, Qin C, Gao Y, Zhang X, Zhang M, Lu Y. MicroRNA-613 suppresses colon cancer proliferation via targeting neurokinin-1. Int J Clin Exp Pathol 2016;9:12511–18.
15. Li D, Li DQ, Liu D, Tang XJ. MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer. Cell Oncol 2016;39:139–47.
16. Zhang X, Zhang H. Diminished miR-613 expression as a novel prognostic biomarker for human ovarian cancer. Eur Rev Med Pharmacol Sci 2016;20:837–41.
17. Cai H, Yao J, An Y, Chen X, Chen W, Wu D, et al. LncRNA HOTAIR acts as competing endogenous RNA to control the expression of Notch3 via sponging miR-613 in pancreatic cancer. Oncotarget 2017;8:32905–17.
18. Wang Y, Zhao P, Qian D, Hu M, Zhang L, Shi H, et al. MicroRNA-613 is downregulated in HCMV-positive glioblastoma and inhibits tumour progression by targeting arginase-2. Tumour Biol 2017;39:1010428317712512.
19. Zhang Y, Zhu X, Zhu X, Wu Y, Liu Y, Yao B, et al. MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5. Tumour Biol 2017;39:1010428317691674.
20. Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R, et al. MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene 2018;659:168–74.
21. Sang Q, Liu X, Sun D. Role of miR-613 as a tumor suppressor in glioma cells by targeting SOX9. Onco Targets Ther 2018;11:2429–38.
22. Yang G, Fu Y, Lu X, Wang M, Dong H, Li Q. LncRNA HOTAIR/miR‐ 613/c‐met axis modulated epithelial‐mesenchymal transition of retinoblastoma cells. J Cell Mol Med 2018;22:5083–96.
23. Zhu Y, Tang L, Zhao S, Sun B, Cheng L, Tang Y, et al. CXCR4‐ mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA‐613. Cancer Sci 2018;109:2412–22.
24. Liu H, Chen K, Wang L, Zeng X, Huang Z, Li M, et al. miR-613 inhibits Warburg effect in gastric cancer by targeting PFKFB2. Biochem Biophys Res Commun 2019;515:37–43.
25. Zhou N, He Z, Tang H, Jiang B, Cheng W. LncRNA RMRP/miR613 axis is associated with poor prognosis and enhances the tumorigenesis of hepatocellular carcinoma by impacting oncogenic phenotypes. Am J Transl Res 2019;11:2801–15.
26. Luo J, Jin Y, Li M, Dong L. Tumor suppressor miR 613 induces cisplatin sensitivity in non small cell lung cancer cells by targeting GJA1. Mol Med Rep 2021;23:385.
27. Su Y, Liang C, Yang Q. LncRNA MALAT1 promotes glioma cell growth through sponge miR-613. JBUON 2021;26:984–91.
28. Yao Q, Zhang L, Wang Y, Liu J, Yang L, Wang Y. LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613. Biosci Rep 2021;41:BSR20201389.
29. Wang Y, Xin D, Zhou L. LncRNA LINC00152 increases the aggressiveness of human retinoblastoma and enhances carboplatin and adriamycin resistance by regulating MiR613/Yes-associated protein 1 (YAP1) axis. Med Sci Monit 2020;26:e920886.
30. Wang L, Chen X, Sun X, Suo J. Long noncoding RNA LINC00460 facilitates colorectal cancer progression by negatively regulating miR-613. Onco Targets Ther 2020;13:7555–69.
31. Li B, Liu D, Yang P, Li HY, Wang D. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene 2019;707:78–85.
32. Liu C, Jiang F, Zhang X, Xu X. Long non-coding RNA UCA1 modulates paclitaxel resistance in breast cancer via miR-613/ CDK12 axis. Cancer Manag Res 2020;12:2777–88.
33. Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics 2014;7:53.
34. Khan J, Lieberman JA, Lockwood CM. Variability in, variability out: Best practice recommendations to standardize preanalytical variables in the detection of circulating and tissue microRNAs. Clin Chem Lab Med 2017;55:608–21.
35. Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun 2014;454:210–4.
36. Veryaskina YA, Titov SE, Zhimulev IF. Reference genes for qPCR-based miRNA expression profiling in 14 human tissues. Med Princ Pract 2022;31:322–32.